The First International Symposium on Pheochromocytoma ... the most accurate screening approach, was recommended as the first-line test for diagnosis; reference intervals should favor sensitivity ...
“Pheochromocytoma and paraganglioma are rare tumors that ... By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure ...
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumours that form in and around the adrenal glands, and ...
b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...
The asymptomatic nature of glaucoma makes it imperative to get consistent screening to catch the condition early.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback